Technologies

HPV+ HNSCC Cell Lines

Tech ID: L-20-002

Background

HPV+ HNSCC (head and neck squamous cell carcinoma) is increasing in occurrence in the HNSCC population around the world. Although there are numerous HPV negative HNSCC cell lines that have been established and that are used as models of HPV negative disease, there is a lack of HPV+ cell lines models for the study of this important aspect of HNSCC. There are approximately 8 HPV type 16 positive HNSCC cell lines available to the research community.

Technology Overview

This invention adds another HPV16 early passage cell line (UWO37), and an HPV33 cell line (UWO23) to the research collection for scientists around the world. In contrast to most if not all previous established HPV positive cell lines, we have made a treatment naive cell line, which might respond differently to targeted treatment. As well, each cell line has a different high risk HPV type (HPV33 and HPV16) associated with it. The two cell lines are described in Oncotarget. 2018; 9: 26064 – 26071(https://doi.org/10.18632/oncotarget.25436).

Benefits/Applications

  • Two cells lines carry and express different human papillomaviruses. Both are low cell passage out of the patient
  • The first HPV33 cell line (UWO23) and it is derived from a treatment naive patient
  • A new HPV16 (UWO37) cell line to increase the options available for the research community
  • Excellent model systems for studying the role of HPV+ in head and neck squamous cell carcinoma (HNSCC)

Keywords

head and neck squamous cell carcinoma, cell lines, human papillomavirus, HPV+

Patricia Pan

Business Development Manager

+1.519.661.3865

Print Friendly, PDF & Email

For Industry

We work with a wide range of industry verticals to help overcome their technical challenges and/or open new and exciting market opportunities. Our team is dedicated to helping both industry and the inventor(s) find the solution that could make a difference to a company and a community.

To learn more, click here.